When was VitroScan founded?

VitroScan was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is VitroScan located?

VitroScan is headquartered in Leiden, Netherlands.

How many employees does VitroScan have?

As of May 31, 2026, the latest employee count at VitroScan is 10.

Is VitroScan a funded company?

VitroScan is a funded company, having raised a total of $901K across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 11, 2019.

When was the latest funding round of VitroScan?

VitroScan's latest funding was a $***** Grant (prize money) round on Dec 02, 2024, with participation from 1 investor. Its primary sector is Oncology. In Netherlands, the Oncology sector has seen $16M in funding in 2026 to date.

Where does VitroScan rank among its competitors?

VitroScan ranks 151st amongst 460 active competitors, of which 131 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Delfi Diagnostics, which secured $34.3M in Dec, 2025.

Who are the top competitors of VitroScan?

VitroScan's top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Delfi Diagnostics secured the most recent funding round in December, 2025.

VitroScan - 2026 Company Profile, Funding & Competitors

Company Details

Provider of a diagnostic platform for precision treatments for cancer patients. The company offers a 3D drug response platform that helps in predicting the drug reactions on the tumor cultures for drug optimization solutions. The platform gives insights by a systematic approach for measuring drug activity via advanced imaging technology and drug response analysis for better clinical outcomes.

Website: vitroscan.nl
Email ID: *****@vitroscan.nl
Phone Number: +31 **********

Key Metrics

Founded Year

2016

Location

Leiden, Netherlands

Stage

Seed

Total Funding

$901K in 2 rounds

Latest Funding Round

Grant (prize money), Dec 02, 2024, $*****

Investors

Libertatis Ergo Holding & 2 more

Ranked

151^st among 460 active competitors

Employee Count

10 as on May 31, 2026

Similar Companies

Guardant Health & 593 more

View VitroScan's full profile

VitroScan has raised a total funding of $901K over 2 rounds. Its first funding round was on Apr 11, 2019. Its latest funding round was a Grant (prize money) round on Dec 02, 2024 for $*****. 1 investor participated in its latest round. VitroScan has 2 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of VitroScan:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 02, 2024	5997379	Grant (prize money)	1717185	9853629	9846576	8634862
Apr 11, 2019	8489106	Seed	9246510	8786391	Libertatis Ergo Holding	Pieter Geelen

Access funding benchmarks and valuations. Sign up today!

View details of VitroScan's funding rounds and investors

VitroScan's employee count trend

VitroScan has 10 employees as of May 26. Here is VitroScan's employee count trend over the years:

Uncover VitroScan's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VitroScan include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of VitroScan, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Lightspeed Venture Partners, Khosla Ventures ... & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Harmony Venture Partners ... & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Google Ventures & 11 others	71/100
5th	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Bank of America, Petrillo Capital & 8 others	71/100
6th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	71/100
7th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Beyond Ventures, Ping An Ventures & 21 others	70/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
9th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	Merck Global Health Innovation Fund, DFJ Growth ... & 19 others	68/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Civilization Ventures & 6 others	66/100
151st	VitroScan 2016, Leiden (Netherlands), Seed	Provider of a diagnostic platform for precision treatments for cancer patients	$901K	Libertatis Ergo Holding, Biotech Booster & 1 others	36/100